Literature DB >> 19902227

Multimodal approach for treatment of peritoneal surface malignancies in a tumour-bearing rat model.

Wieland Raue1, Maik Kilian, Chris Braumann, Vladimir Atanassow, Anna Makareinis, Sonja Caldenas, Wolfgang Schwenk, Jens Hartmann.   

Abstract

PURPOSE: Surgical cytoreduction of peritoneal surface malignancy of colorectal origin in combination with hyperthermic intraoperative peritoneal chemotherapy (HIPEC) has become an established treatment approach. Only a few of animal models for scientific research on various therapeutic strategies have been described yet. The feasibility of an established rat model with a peritoneal surface malignancy from colorectal origin for treatment investigation should be examined in this study.
METHODS: Peritoneal surface malignancy of colonic origin was induced in 90 male BD IX rats. Animals were randomised into six groups (15 animals per one control and five treatment groups). One treatment group underwent only surgical debulking. The animals of the other four treatment groups received additional interventions: hyperthermic intraperitoneal chemotherapy with mitomycin or gemcitabine, photodynamic therapy or taurolidine lavage. Twenty-one days after treatment, the intraperitoneal status was investigated. Tumour weight, count of tumour nodules and experimental Peritoneal Carcinosis Index (ePCI) were detected.
RESULTS: Extended surgical cytoreduction and additional treatments including HIPEC were feasible in this rat model. All treatment groups had a significant lower tumour weight, account of tumour nodes and ePCI if compared with the control group. Comparing the additional therapies only HIPEC with mitomycin lead to relevant tumour reduction after surgery.
CONCLUSION: This rat model is suitable for research on the multimodal treatment of peritoneal malignancies. A persisting cytoreductive effect of surgical tumour debulking could be proven. Only additional HIPEC therapy with mitomycin showed a significant tumour reduction. This animal model provides the opportunity to investigate different therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19902227     DOI: 10.1007/s00384-009-0819-7

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  25 in total

1.  [Effect of intra-abdominal pressure in laparoscopy on intraperitoneal tumor growth and development of trocar metastases. An animal experiment study in the rat model].

Authors:  C A Jacobi; J Ordemann; H U Zieren; J M Müller
Journal:  Langenbecks Arch Chir Suppl Kongressbd       Date:  1998

2.  Intraoperative and early postoperative chemotherapy into the abdominal cavity using gemcitabine may prevent postoperative occurence of peritoneal carcinomatosis.

Authors:  Karsten Ridwelski; Frank Meyer; Arndt Hribaschek; Udo Kasper; Hans Lippert
Journal:  J Surg Oncol       Date:  2002-01       Impact factor: 3.454

3.  Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique.

Authors:  A D Stephens; R Alderman; D Chang; G D Edwards; J Esquivel; G Sebbag; M A Steves; P H Sugarbaker
Journal:  Ann Surg Oncol       Date:  1999-12       Impact factor: 5.344

Review 4.  Taurolidine--a new drug with anti-tumor and anti-angiogenic effects.

Authors:  Christoph A Jacobi; Charalambos Menenakos; Chris Braumann
Journal:  Anticancer Drugs       Date:  2005-10       Impact factor: 2.248

5.  [Impact of pneumoperitoneum on expression of E-cadherin, CD44v6 and CD54 (ICAM-1) on HT-29 colon-carcinoma cells].

Authors:  J Ordemann; C Höflich; C Braumann; J Hartmann; C A Jacobi
Journal:  Zentralbl Chir       Date:  2005-10       Impact factor: 0.942

6.  Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study.

Authors:  O Glehen; F Kwiatkowski; P H Sugarbaker; D Elias; E A Levine; M De Simone; R Barone; Y Yonemura; F Cavaliere; F Quenet; M Gutman; A A K Tentes; G Lorimier; J L Bernard; J M Bereder; J Porcheron; A Gomez-Portilla; P Shen; M Deraco; P Rat
Journal:  J Clin Oncol       Date:  2004-08-15       Impact factor: 44.544

7.  Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy.

Authors:  P H Sugarbaker; K A Jablonski
Journal:  Ann Surg       Date:  1995-02       Impact factor: 12.969

8.  Peritonectomy procedures.

Authors:  P H Sugarbaker
Journal:  Ann Surg       Date:  1995-01       Impact factor: 12.969

9.  The effects of adjuvant experimental radioimmunotherapy and hyperthermic intraperitoneal chemotherapy on intestinal and abdominal healing after cytoreductive surgery for peritoneal carcinomatosis in the rat.

Authors:  F Aarts; R P Bleichrodt; B de Man; R Lomme; O C Boerman; T Hendriks
Journal:  Ann Surg Oncol       Date:  2008-08-19       Impact factor: 5.344

10.  A new survival model for hyperthermic intraperitoneal chemotherapy (HIPEC) in tumor-bearing rats in the treatment of peritoneal carcinomatosis.

Authors:  Joerg O W Pelz; Joerg Doerfer; Werner Hohenberger; Thomas Meyer
Journal:  BMC Cancer       Date:  2005-05-30       Impact factor: 4.430

View more
  5 in total

Review 1.  Advances in the management of peritoneal malignancies.

Authors:  Vahan Kepenekian; Aditi Bhatt; Julien Péron; Mohammad Alyami; Nazim Benzerdjeb; Naoual Bakrin; Claire Falandry; Guillaume Passot; Pascal Rousset; Olivier Glehen
Journal:  Nat Rev Clin Oncol       Date:  2022-09-07       Impact factor: 65.011

2.  Can hyperthermic intraperitoneal chemotherapy efficiency be improved by blocking the DNA repair factor COP9 signalosome?

Authors:  Mathilde Feist; Xiaohua Huang; Joachim M Müller; Beate Rau; Wolfgang Dubiel
Journal:  Int J Colorectal Dis       Date:  2014-04-13       Impact factor: 2.571

3.  Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival of gastric cancer with peritoneal carcinomatosis: evidence from an experimental study.

Authors:  Li Tang; Lie-Jun Mei; Xiao-Jun Yang; Chao-Qun Huang; Yun-Feng Zhou; Yutaka Yonemura; Yan Li
Journal:  J Transl Med       Date:  2011-05-07       Impact factor: 5.531

4.  Innovative substance 2250 as a highly promising anti-neoplastic agent in malignant pancreatic carcinoma - in vitro and in vivo.

Authors:  M Buchholz; B Majchrzak-Stiller; S Hahn; D Vangala; R W Pfirrmann; W Uhl; C Braumann; A M Chromik
Journal:  BMC Cancer       Date:  2017-03-24       Impact factor: 4.430

Review 5.  Photodynamic therapy and photothermal therapy for the treatment of peritoneal metastasis: a systematic review.

Authors:  Amandine Pinto; Marc Pocard
Journal:  Pleura Peritoneum       Date:  2018-12-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.